Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jul 17, 2021 9:20pm
112 Views
Post# 33565879

RE:RE:RE:RE:RE:RE:RE:52 week low

RE:RE:RE:RE:RE:RE:RE:52 week low
StockingUp21 wrote:

how in this world can ppl approve of the job done. Or think someone could do worse if we make change.  Not including results of the experiments. Does not get worse than this.

 

MrMugsy wrote:

 

Doccole wrote:

I am going to be logging in tonight and I will be voting.  I am with you, and I'm not happy with the way this has played out.  You detailed it pretty well. 

This is our chance as retail to show we are not happy, even if the likelyhood of change isn't likely.  



If the likelihood isn't likely ... then what are you saying?
What you're saying is that you don't like him but that you're in the minority.
I believe you are correct in that, if that's what you're saying, but we'll have to wait for the voting to know for sure.
 




The majority of shares are not looking at the share price (IMO) - they are looking at where we've been and where we're going ... and ... they're not making any changes during OTENA negotiations.  

Where have we been:
- loaded up the cash
- reverse split and ready for NASDAQ
- amalgamation and OTENA deal ready
- in control as we go into Phase 3

Never been this self-sufficient.

Where are we going:
- Phase 3, NASDAQ and OTENA deal(s) could all happen late 2021-early 2022
- Moving drugs forward now that we have cash
- New drug development and IP improvments

Never looked prettier.

That's just my opinion ... and ... we'll see if the votes agree with that.

All in my opinion.


<< Previous
Bullboard Posts
Next >>